TABLE 1.

Subject characteristics at time of analysis

SubjectaAge (yr)Duration of HIV infection (yr)bCurrent therapycVirus load (copies/ml)CD4 count (cells/μl)Total HIV-specific CD4 response (SFC/106 cells)dNo. of recognized peptidese
Acute-Rx
    AC2044HAART<501,2231951
    AC21404HAART<504891,1057
    AC32383HAART<505713102
    AC34343HAART<504432050
    AC63382HAART<507321400
    AC82441HAART<501,0822703
    AC87394HAART<5091781511
Acute-STI
    AC02485STI-no HAART5,7907145603
    AC03365STI-no HAART2,8508051,6107
    AC05445STI-no HAART12,90036189024
    AC06425STI-no HAART23,0004272,75018
    AC10365STI-no HAART2677552,03019
    AC14504STI-no HAART2,3005031,87518
    AC15465STI-no HAART17,8005353,12029
    AC26494STI-no HAART82,6006601,48012
    AC46522STI-no HAART2,975888>14,61036
Chronic-Rx
    CRT1331HAART<50172801
    CRT23613HAART<505791200
    CRT3401HAART<506095802
    CRT4523HAART<50146600
    CRT5343HAART<501,1631801
Chronic-no Rx
    CRU1511None16,3008991,3602
    CRU2551None32,8001,0501,5409
    CRU3291None52,7003712954
    CRU4342None23,5001,0512303
    CRU5386None257,0002800
    CRU6382None10,7912391,3658
Controller-LTNP
    CO1343None2121,0821,3209
    CO2444None1,6207981300
    CO5376None<507322503
    CO6507None1,1406727453
    CO7544None3907422306
    LT45010None<508324,54034
    LT63715None7548321,17522
    LT94014None<501,8016407
    LT14487None<501,3408806
  • a Subjects AC20, CRT3, CRU5, CRU6, and LT14 are females. All other individuals are males.

  • b Indicates years of documented HIV-1 infection.

  • c HAART defined as regimen containing at least three drugs.

  • d Sum of responses to the positive peptide pools in IFN-γ ELISPOT in SFC per 106 CD8-depleted PBMC. As each peptide is in two pools, only the responses to the pools with contiguous overlapping peptides were used for the calculation of the total response.

  • e Number of confirmed responses to individual peptides in IFN-γ ELISPOT.